Sugi Predict

Sugi Predict / Compounds / SCHEMBL9904685

SCHEMBL9904685

SCHEMBL9904685

Oc1cccc2c1C1(CCO2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB2 P05107 1/20 0.38
▸ ICAM1 P05362 1/20 0.38
▸ ITGAL P20701 1/20 0.38
▸ LMNA P02545 3/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ CRHBP P24387 2/20 0.34
▸ CRHR2 Q13324 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ MAP3K14 Q99558 3/20 0.33
▸ ADAMTS4 O75173 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ FYN P06241 1/20 0.31
▸ MMP2 P08253 1/20 0.31
▸ MMP9 P14780 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980294 0.82 ADAMTS4 (0.32) ITGB2ICAM1ITGALLMNAADAMTS4
SCHEMBL29913397 0.82 ADAMTS4 (0.32) ITGB2ICAM1ITGALLMNAADAMTS4
SCHEMBL16661511 0.79 ITGB2 (0.37) ITGB2ICAM1ITGALLMNASMN1; SMN2
SCHEMBL6344023 0.75 SMN1; SMN2 (0.33) ITGB2ICAM1ITGALLMNASMN1; SMN2
SCHEMBL21262971 0.69 ALDH1A1 (0.35) ITGB2ICAM1ITGALLMNASMN1; SMN2
SCHEMBL19041436 0.69 ITGB2 (0.48) ITGB2ICAM1ITGALLMNASMN1; SMN2
SCHEMBL31486441 0.69 ITGB2 (0.48) ITGB2ICAM1ITGALLMNASMN1; SMN2
SCHEMBL23279326 0.69 — —
SCHEMBL16659193 0.69 MAOA (0.35) —
SCHEMBL9923782 0.67 PTPN1 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3386506-B1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LTD (GB) 2024-01-24 — — EP disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
EP-3390394-B1 HYDANTOIN MODULATORS OF KV3 CHANNELS AUTIFONY THERAPEUTICS LTD (GB) 2022-05-25 — — EP disclosed
US-20220071998-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2022-03-10 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-11180461-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-11-23 — — US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 — — US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP disclosed
US-20150111910-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2015-04-23 — — US disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111910-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 ITGB2 2044/4885ICAM1 2021/4885ITGAL 2414/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ITGB2 3300/4885ICAM1 1289/4885ITGAL 3033/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ITGB2 3300/4885ICAM1 1289/4885ITGAL 3033/4885
US-11180461-B2 Triazoles as Kv3 inhibitors KCNA3, KCNN3, KCNK3 ITGB2 2044/4885ICAM1 2021/4885ITGAL 2414/4885
US-20220071998-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 ITGB2 2422/4885ICAM1 1388/4885ITGAL 1734/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ITGB2 3910/4885ICAM1 1399/4885ITGAL 3508/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ITGB2 3300/4885ICAM1 1289/4885ITGAL 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.